Cancer Treatment News and Research

RSS

New fund could enable early access to life-saving treatments for NHS patients in England

NNHS patients in England will have early access to potentially life-saving and cutting-edge treatments thanks to a new fund which has been launched today.

6 Jun 2022

COVID-19's economic impact on healthcare systems, societies, and the population

In a recent study review posted to the medRxiv* preprint server, researchers evaluated the economic and medical costs incurred due to the coronavirus disease 2019 (COVID-19) pandemic.

6 Jun 2022

New "masked" version of immunotherapy could help fight cancer without causing side effects

Many cancer treatments are notoriously savage on the body; they attack healthy cells at the same time as tumor cells, causing a plethora of side effects.

1 Jun 2022

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies, according to a study published in the Journal of Clinical Oncology.

31 May 2022

New discovery could pave the way for more effective cancer immunotherapy

A type of white blood cell previously known only as a helper in the immune system appears also to be the instigator of the body's defenses against cancerous tumors.

31 May 2022

New compounds for cancer immunotherapy via STING-mediated immune activation

Innovations in cancer immunotherapy have achieved clinical success by considerably increasing the survival rate of patients undergoing cancer treatment.

31 May 2022

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade.

30 May 2022

HMA therapy for patients with myelodysplastic syndrome could potentially activate a sleeping oncogene

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.

26 May 2022

Patient’s perspective on their physical well-being can help better predict cancer treatment outcomes

A breast cancer patient’s perspective on their physical well-being can provide a better indication of their response to cancer treatment than clinician-based tools, a new study has found, highlighting the importance of shared decision-making in the treatment process.

26 May 2022

New initiative aims to increase collaboration and accelerate high-impact cancer immunotherapy

The accelerated advancement of cancer immunology and immunotherapy, a type of biological therapy that boosts the immune system's ability to recognize and kill cancer cells, has significantly improved the effectiveness of cancer treatment and patient outcomes.

25 May 2022

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

24 May 2022

The Sheri and Les Biller Family Foundation's $10 million gift will support City of Hope’s supportive care program for cancer patients

City of Hope, one of the largest cancer research and treatment organizations in the United States and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, has received a $10 million gift from The Sheri and Les Biller Family Foundation.

24 May 2022

Widely used Type 2 diabetes drug does not prevent breast cancer spread, landmark trial finds

A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease, according to new findings.

24 May 2022

'Crown-like structures' surrounding breast tumors could hinder treatment response, study finds

A new study from the University of Southampton has discovered that 'crown-like structures' surrounding breast tumors in overweight and obese patients could hinder their response to therapy.

24 May 2022

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

The National Comprehensive Cancer Network today announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.

23 May 2022

Hyperinsulinemic patients with breast cancer may be responsive to metabolism-targeting treatments

Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.

20 May 2022

Intestinal microbiome may contribute to the pathogenesis of MSI colon cancers, study suggests

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey's only National Cancer Institute- Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors.

19 May 2022

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

In a new study, researchers evaluated the BNT162b2 coronavirus disease 2019 mRNA vaccine (antigen)-specific immune response among myeloid dysplastic syndrome and chronic lymphocytic leukemia patients.

18 May 2022

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

18 May 2022

Polypharmacy can lead to harmful drug interactions, especially among cancer patients

Here's a scenario so common that it applies to nearly 92 percent of older adults with cancer: An individual comes in for treatment and reports taking several medications that might include a drug for high blood pressure or heart disease, an antidepressant, or something for diabetes.

17 May 2022

Cancer Treatment News and Research

New fund could enable early access to life-saving treatments for NHS patients in England

COVID-19's economic impact on healthcare systems, societies, and the population

New "masked" version of immunotherapy could help fight cancer without causing side effects

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

New discovery could pave the way for more effective cancer immunotherapy

New compounds for cancer immunotherapy via STING-mediated immune activation

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

HMA therapy for patients with myelodysplastic syndrome could potentially activate a sleeping oncogene

Patient’s perspective on their physical well-being can help better predict cancer treatment outcomes

New initiative aims to increase collaboration and accelerate high-impact cancer immunotherapy

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

The Sheri and Les Biller Family Foundation's $10 million gift will support City of Hope’s supportive care program for cancer patients

Widely used Type 2 diabetes drug does not prevent breast cancer spread, landmark trial finds

'Crown-like structures' surrounding breast tumors could hinder treatment response, study finds

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

Hyperinsulinemic patients with breast cancer may be responsive to metabolism-targeting treatments

Intestinal microbiome may contribute to the pathogenesis of MSI colon cancers, study suggests

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Polypharmacy can lead to harmful drug interactions, especially among cancer patients

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News